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To the Editor, 
We read with interest the paper from Montagenese et al. (2016) on the possible use of two novel 
approaches to determine ´neuropsychiatric normality´ in the context of a diagnosis of hepatic 
encephalopathy (HE) [1].  The authors challenge the conventional use of psychometric and 
neurophysiological testing based on reference to normative data and suggest that there may be advantages 
in defining ‘normality’ in terms of single patients’ lifelong performance and/or in terms of risk. Three cases 
serve as examples for the relevance of the suggested approaches. 
  
Better optimised tools and tactics for diagnosing HE would undoubtedly be welcomed; we do, however, 
have several concerns about both the proposed approaches.  Semantic inconsistencies make it difficult to 
determine the exact approach in the system based on ’best performance’.  First, it is unclear how the 
authors utilize the term ´baseline performance´. Thus, if a patient presents initially with overt HE, then any 
improvement/deterioration in their neuropsychiatric status would be judged against this baseline state.  
This, however, does not appear to be the way in which the term is applied; rather it appears that authors 
when referring to ´baseline performance´ actually mean ‘best performance since the diagnosis of cirrhosis 
was established’.  Second, it appears that this best performance is equated to ´top personal performance´ 
but these are far from the same; top personal performance is likely to have been attained before the 
person developed cirrhosis and could differ significantly from their best performance since that time.  The 
arbitrary defined ´personal best` would also have to be adapted as the person ages.  Third, neuropsychiatric 
comorbidities may compromise the ´personal best performance´ and thus bias the assessment of HE as 
illustrated in Case 2 where the authors state that an abnormal Mini Mental State Examination precluded 
testing for HE.  We are not aware of any data that support this contention and are unsure why this patient 
was diagnosed with underlying alcohol-related, dietary-related, cerebro-vascular psychopathology rather 
than intractable, partially responsive chronic HE.  The electroencephalogram (EEG) was grossly abnormal 
and although slowing of the mean cycle frequency may be observed in people with dementia, this degree 
of EEG abnormality if attributable to dementia per se, would be accompanied by a far greater degree of 
clinical abnormality than just ‘inappropriateness’ [2].  Finally, as neuropsychiatric comorbidities and age 
effects may compromise the ´personal best performance´, utilization of this information and, in the 
absence of normative reference data, its translation into guidelines useful for health systems and legislators 
would present considerable difficulties.  Similar difficulties would arise with the utility of this system for 
clinical decision making, for example, in relation to driving [3]. 
The second proposed approach, for use in conjunction with the first or as a stand alone system, is to 
replace ‘reference thresholds’ with ‘risk thresholds; defined by their ability to separate individuals who are 
likely or unlikely to develop an HE-related hospitalization in the future [1].  The authors provide illustrative, 
  
but not validated data, showing that a PHES threshold of -2 and a spectral EEG Theta power threshold of 
30% better predict the development of HE-related hospitalization over both 12 and 18 months than the 
current reference thresholds of -4 and 35% respectively.  Selection of the risk thresholds was based on the 
lowest Cox-Mantel p value but performance data for these thresholds were not provided.   
 
The major difficulty with these approaches is that they do not provide point diagnostic information and 
thus are not of value to clinicians who need to decide whether to treat a patient for HE at a given point in 
time; given the low toxicity of treatments prescribed for HE [4], it is hardly operational to wait for 
longitudinal data to see if the patient truly has HE or whether they may develop HE at some point in the 
future.  As an alternative we would advocate retention of normative thresholds.  These, however, need to 
be revisited, defined more appropriately, and validated prospectively to improve diagnostic and predictive 
validity.  With this in mind we recently identified new spectral EEG thresholds for the diagnosis of any 
degree of HE and validated them in two independent populations and by reference to performance 
variables obtained using a machine learning technique [5].  The performance characteristics of these new 
thresholds, the most radical of which was the reduction in the theta activity threshold from <35% to 
<22.7%, are superior and better balanced than the thresholds currently employed [5].  Had Montagnese et 
al. [1] adopted these new EEG thresholds, and our paper was referenced in their text, then Cases 1 and 3 
could have been correctly classified, based on their EEG findings.  As such, the newly derived spectral 
thresholds may improve the utility of the EEG for the diagnosis of any degree of HE in clinical practice.  
 
The major challenge in this patient population is the accurate diagnosis of neuropsychiatric impairment and 
a determination of its clinical relevance including, but not be confined to, a risk assessment.  While the 
proposals have some merit, their practicality and utility must be questioned, at this time.  
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